WHAT IS COMING NEXT?
Registered development, sponsor announcements and UK readiness implications are shown separately. A Phase 3 programme or filing plan is not an approval.
Phase 3 programme; sponsor has announced a planned regulatory filing
A near term example of demand arriving ahead of regulatory approval. It is widely discussed and marketed illicitly while remaining investigational.
UK readiness 6/10 · Very high grey market interest exposure
Open recordPhase 3 monotherapy programme
Important as a monotherapy candidate and as the amylin component of CagriSema, illustrating expansion beyond GLP-1 alone.
UK readiness 5/10 · High research market interest exposure
Open recordPhase 3 obesity programme initiated in 2026
Formerly amycretin, this single molecule peptide is being developed in injectable and oral forms.
UK readiness 4/10 · Emerging exposure
Open recordGlobal Phase 3 MASH development
Broadens peptide readiness beyond weight loss into liver disease and the convergence of metabolic and hepatology pathways.
UK readiness 4/10 · Emerging exposure
Open recordGlobal Phase 3 obesity and MASH programmes
A late stage dual agonist with parallel obesity, liver and cardiovascular development.
UK readiness 4/10 · Emerging exposure
Open record